Free tool
FAERS Monitor: Silvadene
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017381 or its brand name (Silvadene, Silver Sulfadiazine). Reports on generic versions are filed under their own applications.
Reports
2,294
Serious
1,488
65% of reports
Hospitalization
779
Death reported
290
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use161
- pain152
- fatigue150
- product use in unapproved indication146
- nausea136
- death121
- diarrhoea118
- drug ineffective115
- chronic kidney disease109
- dyspnoea108
- rash99
- anxiety95
- fall95
- pneumonia93
- acute kidney injury90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 17 |
| 2006 | 16 |
| 2007 | 26 |
| 2008 | 17 |
| 2009 | 42 |
| 2010 | 35 |
| 2011 | 34 |
| 2012 | 78 |
| 2013 | 49 |
| 2014 | 67 |
| 2015 | 98 |
| 2016 | 200 |
| 2017 | 151 |
| 2018 | 181 |
| 2019 | 185 |
| 2020 | 194 |
| 2021 | 204 |
| 2022 | 176 |
| 2023 | 160 |
| 2024 | 119 |
| 2025 | 112 |
| 2026 | 112 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,865 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 109 | 13.2 | 11.0 | 1,216 |
| product use in unapproved indicationSignal | 146 | 5.4 | 4.6 | 525 |
| acute kidney injurySignal | 90 | 5.4 | 4.4 | 320 |
| anxietySignal | 95 | 3.1 | 2.5 | 132 |
| pneumoniaSignal | 93 | 2.6 | 2.2 | 94 |
| fallSignal | 95 | 2.6 | 2.1 | 95 |
| painSignal | 152 | 2.3 | 1.9 | 110 |
| rashSignal | 99 | 2.1 | 1.7 | 56 |
| fatigue | 150 | 1.8 | 1.5 | 51 |
| dyspnoea | 108 | 1.7 | 1.5 | 35 |
| off label use | 161 | 1.7 | 1.5 | 46 |
| diarrhoea | 118 | 1.7 | 1.4 | 33 |
| nausea | 136 | 1.6 | 1.3 | 29 |
| death | 121 | 1.3 | 1.1 | 8 |
| drug ineffective | 115 | 0.8 | 0.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.